과제정보
이 논문은 충남대학교 학술연구비 및 2020년도 정부(과학기술정보통신부)의 재원으로 정보통신기획평가원(No. 2020-0-01441, 인공지능융합연구센터(충남대학교))의 지원을 받아 수행된 연구입니다.
참고문헌
- Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012;23(Suppl 8):viii6-9. https://doi.org/10.1093/annonc/mds256
- Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: Management of immunotherapy-related toxicities, Version 1.2020. J Natl Compr Canc Netw 2020;18(3):230-41. https://doi.org/10.6004/jnccn.2020.0012
- US Food and Drug Administration. Drug approval package: pembrolizumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000TOC.cfm. Accessed November 20, 2020.
- US Food and Drug Administration. Drug approval package: nivolumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000TOC.cfm. Accessed November 20, 2020.
- US Food and Drug Administration. Drug approval package: atezolizumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034Orig1s000TOC.cfm. Accessed November 20, 2020.
- US Food and Drug Administration. Drug approval package: ipilimumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125377orig1s000toc.cfm. Accessed November 20, 2020.
- US Food and Drug Agency. Drug approval package: durvalumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761069Orig1s000TOC.cfm. Accessed November 20, 2020.
- Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs 2016;30(6):571-84. https://doi.org/10.1007/s40259-016-0204-3
- Liu YH, Zang XY, Wang JC, Huang SS, Xu J, Zhang P. Diagnosis and management of immune related Adverse events (irAEs) in cancer immunotherapy. Biomed Pharmacother 2019;120:109437. https://doi.org/10.1016/j.biopha.2019.109437
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64. https://doi.org/10.1038/nrc3239
- Mok, TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet 2019;393(10183):1819-30. https://doi.org/10.1016/S0140-6736(18)32409-7
- Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract 2018;139:203-20. https://doi.org/10.1016/j.diabres.2018.03.006
- Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol 2018;4(2):173-82. https://doi.org/10.1001/jamaoncol.2017.3064
- Clotman K, Janssens K, Specenier P, Weets I, De Block CEM. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab 2018;103(9):3144-54. https://doi.org/10.1210/jc.2018-00728
- World Health Organization, International Diabetes Institute, International Association for the Study of Obesity (IASO). The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia. Available from https://apps.who.int/iris/handle/10665/206936. Accessed September 10, 2021.
- Tatsuno I, Sugiyama T. Glucocorticoid-induced diabetes mellitus is a risk for vertebral fracture during glucocorticoid treatment. Diabetes Res Clin Pract 2011;93(1):e18-20. https://doi.org/10.1016/j.diabres.2011.03.005
- de Filette JMK, Pen JJ, Decoster L, et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol 2019;181(3):363-74. https://doi.org/10.1530/EJE-19-0291
- Korea Diabetes Association, Clinical Practice Guidelines for Diabetes 2021. Available from https://www.diabetes.or.kr/pro/publish/guide.php?code=guide&number=853&mode=view. Accessed September 10, 2021.
- Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008;93(7):2447-53. https://doi.org/10.1210/jc.2007-2174
- Magis Q, Gaudy-Marqueste C, Basire A, et al. Diabetes and blood glucose disorders under anti-PD1. J Immunother 2018;41(5):232-40. https://doi.org/10.1097/CJI.0000000000000218